Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaborem in Pediatric Gram Negative Infections
NCT06828848Phase 2Recruiting
- Sponsor
- Menarini Group
- Start
- Feb 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of meropenem + vaborbactam in Gram-negative bacterial infection, sponsored by Menarini Group. Primary endpoints: Area under the concentration-time curve at Day 3, Maximum plasma concentration at Day 3 and 3 more. Started Feb 2025; status: recruiting.
02
Drugs
meropenem + vaborbactam
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT06828848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06828848.